Stifel Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)

Mirum Pharamceuticals (MIRM) PT Raised to $62 at Evercore ISI

Evercore ISI analyst Gavin Clark-Gartner raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $62.00 (from $53.00) while maintaining a Outperform rating.

The analyst comments "MIRM is one of the rare, profitable smallcaps in our coverage based on their base business alone (which... More

Mirum Pharamceuticals (MIRM) PT Raised to $64 at Citi

Citi analyst David Lebowitz raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $64.00 (from $38.00) while maintaining a Buy rating.

The analyst comments "In todays call, Mirum highlighted that volixibat performance in both PSC & PBC beat expectations. Early best-in-disease itch... More

Mirum Pharamceuticals (MIRM) PT Raised to $57 at Morgan Stanley

Morgan Stanley analyst Michael E Ulz raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $57.00 (from $53.00) while maintaining a Overweight rating.

The analyst comments "Interim Ph2b volixibat results better than expected, as robust activity observed in PBC and blinded analysis in... More

Mirum Pharamceuticals (MIRM) PT Raised to $39 at Baird

(Updated - June 17, 2024 9:06 AM EDT)

Baird analyst Brian Skorney raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $39.00 (from $34.00) while maintaining a Outperform rating.

The analyst commented: "Raising target price on positive volixibat results. Volixibat demonstrated unprecedented reductions... More

Citi Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)

Citi analyst David Lebowitz reiterated a Buy rating and $38.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM)

The analyst comments "This morning, Mirum shared positive interim updates from volixibats Ph2b VISTAS and VANTAGE trials in primary sclerosing cholangitis (PSC) and primary biliary cholangitis... More

Mirum Pharmaceuticals' (MIRM) Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced interim results from two Phase 2b studies evaluating volixibat, an oral ileal bile acid transporter (IBAT) inhibitor in patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).

Interim results from the VANTAGE study... More